Richard K. Prins, a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), disclosed the sale of 5,000 shares of the company's common stock. The shares were sold at a weighted average price of approximately $48.80, totaling $243,985. Following this transaction, Prins' direct ownership stands at 31,471 shares.
Additionally, Prins acquired 2,500 shares through the exercise of stock options at a price of $16.69 per share, bringing the total value of this acquisition to $41,725. After these transactions, Prins holds 4,179 shares under direct ownership.
These transactions were reported in a Form 4 filing with the Securities and Exchange Commission, dated November 12, 2024.
In other recent news, Amphastar Pharmaceuticals Inc. has disclosed its third-quarter earnings results. The company's executives, including CFO Bill Peters, Senior Vice President Dan Dischner, and Executive Vice President Tony Marrs, led the earnings call, discussing key financial results and providing their outlook for future periods. These forward-looking statements, as emphasized by the company, are based solely on information currently available and are subject to numerous factors that may impact future performance.
In an effort to provide investors with a clear understanding of the company's financials, non-GAAP measures were also discussed, with important information and reconciliations to U.S. GAAP provided in the earnings release. The company reminded listeners to review the forward-looking statements section in the press release, presentation, and the company's SEC filings.
Recent developments also included an interactive question-and-answer session following the formal presentation, allowing participants to engage with the company's executives. These are some of the recent highlights from Amphastar Pharmaceuticals Inc.'s third-quarter earnings call.
InvestingPro Insights
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has been showing strong financial performance, which provides context to the recent insider transactions. According to InvestingPro data, the company's revenue grew by 20.33% over the last twelve months, reaching $723.55 million. This growth is complemented by a robust EBITDA margin of 29.29%, indicating efficient operations.
Despite the recent stock sale by director Richard K. Prins, InvestingPro Tips suggest that management has been aggressively buying back shares, which could signal confidence in the company's future prospects. This buyback activity aligns with the company's strong financial position, as liquid assets exceed short-term obligations.
The stock's valuation metrics are also noteworthy. With a P/E ratio of 14.12 and a PEG ratio of 0.84, AMPH appears to be trading at a reasonable valuation relative to its growth potential. An InvestingPro Tip highlights that the stock is trading at a low P/E ratio relative to near-term earnings growth, which could be attractive for value-oriented investors.
It's worth noting that while the stock has experienced a 26.47% decline year-to-date, analysts remain optimistic. The fair value based on analyst targets is $57.5, suggesting potential upside from the current price of $47.71.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights. There are 7 more InvestingPro Tips available for Amphastar Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.